Ascrinvacumab

Ascrinvacumab
Monoclonal antibody
Type	?
Source	Human
Target	activin receptor-like kinase 1
Clinical data
Other names	PF-03446962
ATC code	none;
Identifiers
CAS Number	1463459-96-2 ;
ChemSpider	none;
UNII	716FQ5REVO ;
KEGG	D11709 ;
Chemical and physical data
Formula	C6396H9850N1694O2012S44
Molar mass	144079.64 g·mol−1

Last updated February 06, 2023

Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.^[1]

This drug was developed by Pfizer Inc.

References

↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Ascrinvacumab, American Medical Association .

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Ascrinvacumab, American Medical Association .

[1]